

Combining Rapid Antigen Testing and Syndromic Data Improves Sensitivity and Specificity in Real-World COVID-19 Detection

Fergus J Chadwick^{a,b}, Yacob Haddou^{a,b}, Tasnuva Chowdhury^a, David Pascall^d,
Shayan Chowdhury^e, Jessica Clark^{a,b}, Joanna Andrecka^f, Mikolaj
Kundergorski^{c,b}, Craig Wilkie^{c,b}, Eric Brum^f, Tahmina Shirin^g, A S M
Alamgir^g, Mahbubur Rahman^g, Ahmed Nawsher Alam^g, Farzana Khan^g, Janine
Illian^{c,b}, Ben Swallow^{c,b}, Davina L Hill^{a,b}, Dirk Husmeier^c, Jason
Matthiopoulos^{a,b}, Katie Hampson^{a,b}, Ayesha Sania^h

^a*Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow*

^b*COVID-19 in LMICs Research Group, University of Glasgow*

^c*School of Mathematics and Statistics, University of Glasgow*

^d*MRC Biostatistics Unit, University of Cambridge*

^e*a2i Programme, ICT Ministry/UNDP Bangladesh*

^f*UN FAO in support of the UN Interagency Support Team, Bangladesh*

^g*Institute of Epidemiology, Disease Control and Research, Ministry of Health, Bangladesh*

^h*Division of Developmental Neuroscience, Department of Psychiatry, Columbia University*

1. Abstract (Max 250 Words - Currently over)

Background

The majority of the world's population live in low- and middle-income countries where access to gold-standard diagnostics like RT-PCR is often limited. Rapid antigen testing (RAT) and syndromic diagnosis are two alternative, inexpensive and easy-to-deploy surveillance methods but there are concerns that they lack the sensitivity and specificity to effectively guide practice.

Methods

Bangladesh's Institute of Epidemiology Disease Control And Research (IEDCR) identified potential COVID-19 patients in Dhaka using syndromic surveillance.

*Corresponding Author

Email addresses: f.chadwick.1@research.gla.ac.uk (Fergus J Chadwick), yacob.haddou@glasgow.ac.uk (Yacob Haddou), tasnuvachowdhury2004@gmail.com (Tasnuva Chowdhury), david.pascall@mrc-bsu.cam.ac.uk (David Pascall), shayan.chowdhury@a2i.gov.bd (Shayan Chowdhury), Jessica.Clark@glasgow.ac.uk (Jessica Clark), aandrecka@gmail.com (Joanna Andrecka), mikolaj.kundergorski@gmail.com (Mikolaj Kundergorski), craig.wilkie@glasgow.ac.uk (Craig Wilkie), eric.brum@fao.org (Eric Brum), tahmina.shirin14@gmail.com (Tahmina Shirin), aalamgir@gmail.com (A S M Alamgir), dr_mahbub@yahoo.com (Mahbubur Rahman), anawsher@yahoo.com (Ahmed Nawsher Alam), farzanakhan_25@yahoo.com (Farzana Khan), janine.illian@glasgow.ac.uk (Janine Illian), ben.swallow@glasgow.ac.uk (Ben Swallow), davina.hill@glasgow.ac.uk (Davina L Hill), dirk.husmeier@glasgow.ac.uk (Dirk Husmeier), jason.matthiopoulos@glasgow.ac.uk (Jason Matthiopoulos), katie.hampson@glasgow.ac.uk (Katie Hampson), ays328@mail.harvard.edu (Ayesha Sania)

28 A sample ($n = 1172$) of these patients was tested using RAT and syndromic data
29 were collected. Models were fit to predict RT-PCR status using the RAT data,
30 the syndromic data, and the two combined. Model performance was measured
31 using predictive power and classification performance under three epidemiological
32 scenarios: “Agnostic,” “Rising Cases” and “Low-Level Cases.”

33 *Findings*

34 Combined data models yielded equal or improved performance over syndromic-
35 and RAT-only models. For predictive performance, the cross entropy for the
36 models were 1.44, 2.52, and 3.24, respectively.

37 In the first scenario, the median error rates were 0.34, 0.98, and 0.34, respectively.

38 In the second scenario, the median error rates were ∞ , 0.82, and 0.48, respectively.

39 In the final scenario, the median error rates were 0.32, 0.82, and 0.25, respectively.

40 *Interpretation*

41 Inexpensive and accessible surveillance methods are essential for pandemic
42 control in low- and middle- income countries. These methods are imperfect, with
43 much lower sensitivity and specificity than gold-standard methods like RT-PCR.
44 We demonstrate that by exploiting complementary strengths and weaknesses
45 across two imperfect diagnostics, we can greatly improve the detection of COVID-
46 19.

47 *Funding*

48 The Bill and Melinda Gates Foundation and the Wellcome Trust.

Add CIs to
median error
rates.

50 **2. Introduction (~1107 Words)**

51 Identification and isolation of COVID-19 cases remains key to the pandemic
52 response across the globe. The faster and more accurately we can identify cases,
53 the more effectively we can provide clinical care, reduce transmission of infection
54 and develop population-level interventions. RT-PCR testing has rapidly become
55 the default, gold-standard test for COVID-19 in applied settings due to its high
56 sensitivity and specificity for COVID-19 [2]. Most of the world’s population,
57 however, live in low- and middle-income countries where the laboratory facilities
58 needed to carry out RT-PCR tests are often scarce and hard to reach [4]. COVID-
59 19 diagnosis worldwide, therefore, must be made accessible using inexpensive
60 methods that can be carried out locally [6].

61 An increasingly popular alternative to RT-PCR is rapid antigen testing
62 (RAT) [7]. Like RT-PCR, these tests have high specificity for COVID-19 while
63 being less expensive, easier to implement, and faster to produce results [8].
64 RATs also require less commitment and discomfort for patients. For RT-PCR
65 testing, patients must travel to a designated site (such as a hospital or testing
66 booth) or have highly visible PPE-clad officials visit their home. Then, invasive
67 nasopharyngeal swabs must be taken and there is a delay in receiving the result
68 (between one day and a week in Bangladesh). In contrast, RAT can be conducted
69 on nasal or saliva samples, completed in the home with minimal PPE and results
70 are available in 30 minutes. RATs can be taken by persons with limited training,

71 thus decreasing the time and expense associated with identifying cases. Together,
72 these traits make RATs an appealing alternative to RT-PCR. However, several
73 concerns have been raised about the sensitivity of RAT [9] leading to more false
74 negative diagnoses.

75 Another alternative to RT-PCR, one that has been used since the start of
76 the pandemic, is identifying cases through symptom-thresholding [10]. In this
77 approach, a patient presenting with a fever and one or more viral pneumonia
78 symptoms is treated as a COVID-19 positive patient. The main advantage of
79 this approach is the ease of implementation. As with RAT the process is faster,
80 cheaper and less invasive than RT-PCR, but unlike RAT the process relies on
81 minimal equipment and thus can be scaled quickly and easily. For example, in
82 Bangladesh, a lower middle-income country, much of the initial support and
83 reporting of infections locally is provided by community support teams (CSTs)
84 composed of local volunteers with basic training. The CSTs can easily collect
85 symptomatic data in the community and provide care where the criteria are met.
86 However, these symptom-thresholds were developed early in the outbreak, and
87 thus necessarily drawn from clinical intuition, rather than data. Consequently,
88 the relationship between the criteria and the true COVID-19 status is often weak,
89 with low specificity leading to a very large number of false positive diagnoses.

90 A natural extension to these symptom-threshold approaches is syndromic
91 modelling. Here, a patient presenting with a fever and one or more viral
92 pneumonia symptoms is treated as a potential COVID-19 patient. However,
93 rather than using a set of pre-determined criteria, a range of symptomatic and
94 risk factor data are collected and then a sub-sample of patients is tested using
95 RT-PCR for COVID-19 [11]. These data are used to fit a model that allows
96 more accurate prediction of how likely a patient is to have COVID-19 through
97 the identification of COVID-19 syndromes [13]. It is worth highlighting at this
98 point that in resource-limited settings, there is very limited provision for testing
99 of asymptomatic cases, despite their important role in disease transmission [14].
100 Even while focusing solely on symptomatic patients, syndromic modelling is a
101 complex and nuanced task. The strength of relationships between symptoms
102 and diseases is not stable through time or across sampling strategies since the
103 relative importance of each symptom for disease diagnosis, in part, depends on
104 the prevalence of other diseases causing similar symptoms in the community
105 [15]. For example, if another disease for which loss of smell is a symptom
106 becomes common, that symptom becomes a worse predictor for COVID-19.
107 Similarly, if everyone who presents has a cough and thus is included in the
108 sample, then coughing will likely have a very low correlation with COVID-19
109 (even if the two are strongly related in the general population). While these
110 issues can be overcome by properly considering the population sampled and
111 using appropriately sophisticated statistical methods, the many types of common
112 respiratory disease generally means that even then these models tend to have
113 relatively high false positive rates (low specificity) for COVID-19 [15], although
114 much lower than the symptom-threshold approach.

115 Poor sensitivity and specificity are problematic in diagnostics but higher
116 error rates than gold-standard methods may be tolerable depending on their

scale and impact given the local situation. Low specificity means a large number of false positive classifications, where the patient is told they have COVID-19 but they actually do not. This might lead to patients unnecessarily self-isolating and receiving support which can be expensive to the individuals and local public health bodies, as well as reducing available resources for those who need them [16]. Similarly, low sensitivity means more false negative classifications, where the patient is told they do not have COVID-19 but they actually do, which can lead to a health-risk for the individual and to the disease spreading further [17]. The costs of these misclassifications will depend on local context. When the prevalence of the disease is low, false positives may create local scepticism about the value of testing, or when there are strong population-level mitigations already in place (such as a nationwide lockdown), then false positives might be more costly than false negatives [16]. If the disease is abundant or increasing rapidly then false negatives are likely to be more costly. In most situations, a balance will need to be struck [4].

The two dominant “alternative” testing methods available in resource limited settings, therefore, are both flawed. Relying solely on symptomatic diagnosis will likely overestimate the number of individuals with COVID-19 due to its lack of specificity. Conversely, RATs will give a false impression of control due to the number of positive cases that will be missed. In this paper, we demonstrate how to combine these data types to exploit their complementarity and ameliorate their respective weaknesses. We aim to compare the performance of these two testing methods and the combined approach both in terms of general prediction and as diagnostics under three epidemiological scenarios; and demonstrate that the combined data achieve equal to much lower error rates than the next best method. We then discuss the role of statistically integrating data from multiple imperfect testing methods in resource limited settings to improve the diagnosis of diseases, particularly COVID-19.

3. Methods (~1019 Words)

Participants included in this study were identified for COVID-19 testing after self-reporting symptoms to the Bangladesh government’s national hotlines for COVID-19 support. Recruitment took place across Dhaka (the capital city of Bangladesh) between 2nd April 2021 and 5th May 2021.

Patients were selected for further testing conditional on the presence of a fever ($>38^{\circ}\text{C}$) at the point of testing and one or more of 14 additional symptoms associated with COVID-19 (breathing problems, coughing, diarrhoea, fever (ongoing), a headache, loss of taste, loss of smell, muscle pain, red eyes, a runny nose, a sore throat, tiredness, vomiting or a wet cough). The patient’s age and gender were also recorded, but these data were not included in the patient selection criteria.

Nasal swabs and syndromic data were collected from the patient by medical technologists. One swab each was used for rapid antigen testing (RAT) and RT-PCR (gold-standard for COVID-19 status). The full questionnaire and testing protocols are provided in Appendix XX. Participants provided written




Figure 1: Schematic description of identification of likely COVID-19 patients by community support teams (CSTs), swab collection and model definitions. The teams collected syndromic data (age, gender and presence/absence of 14 predetermined symptoms), and two sets of naso-pharyngeal swabs (one each for Rapid Antigen Testing and RT-PCR). We then used rapid antigen testing (RAT) and syndromic data, two imperfect but inexpensive diagnostics, to generate three model classes: RAT result only in Model Class 1, syndromic data only in Model Class 2, and both RAT result and syndromic data in Model Class 3. The RT-PCR test result is used to train and test each model using temporal cross validation.

161 informed consent to sample collection and for their test results to be analyzed in
 162 the study.

163 We examined the ability of the two imperfect identification methods, the
 164 syndromic profile and RAT result, to predict the patient’s COVID-19 status
 165 when used separately and together. The different data combinations define three
 166 model classes (Figure 1).

167 Model Class 1 uses only the RAT result and is the simplest of the three.
 168 It simply equates a positive RAT result with the patient being PCR positive,
 169 and a negative RAT result with PCR negativity. Model Class 2 uses only the
 170 syndromic data and Model Class 3 combines the RAT result with the syndromic
 171 data.

172 For Model Class 2, we used a Bayesian multivariate probit model [18]. The
 173 multivariate probit structure allows the model to account for the correlations
 174 between, and binary nature of, the symptoms (e.g. loss of taste is often correlated
 175 with loss of smell). By using a Bayesian formulation, we are able to better quantify

Find more
ways to cite
Figure
refig:data-
flowchart in
this text.

176 the uncertainty in the parameter estimates. Structurally, the multivariate probit
177 model allows the symptoms and COVID-19 status to be treated as correlated
178 binary outcomes with an intrinsic rate (the intercept for each variable) and the
179 patient’s age and gender, while propagating and quantifying uncertainty.

180 In Model Class 3, we model RAT positive patients as PCR positive and
181 use the syndromic approach outlined for Model Class 2 for the RAT negative
182 patients. The models were fitted to the data using Hamiltonian Monte Carlo in
183 the Stan programming language [19].

184 We conducted backwards model selection (starting with the most complex
185 model feasible, with all 14 symptoms and both covariates) to identify a subset of
186 models with the highest predictive power under temporal cross validation (Figure
187 2). Reducing the number of possible models to a small number of the most
188 predictive models was necessary to reduce computational demand and reduce the
189 risk of overfitting models to the test scenarios. The large number of symptoms
190 means that there is a high number of potential model configurations ($>131\,000$
191 for 14 symptoms and two covariates) which might, by chance, perform well on
192 the test sets (even under the challenging conditions of temporal cross validation)
193 but lack transferability. By first using general predictive power to narrow down
194 the number of candidate models and then testing those models under more
195 specific scenarios, we are more likely to choose models which generalise well
196 to new data. The number of candidate models used was not pre-determined.
197 In fitting the models it became clear that there were “jumps” in performance
198 (as defined below) between models containing five and four symptoms, so the
199 models with zero to four symptoms were used as the candidate models.

200 We scored the models’ predictive power using cross entropy. Cross entropy
201 measures the accuracy of probabilistic predictions for models that predict binary
202 outcomes using probabilities [20], similar in concept to a mean squared error.
203 A cross entropy value close to zero corresponds to high levels of accuracy, with
204 larger values indicating lower accuracy. As the score only uses the predicted
205 probability and true values, it is possible to directly compare the predictions
206 of any model for the same test set. More details on the model structure and
207 selection process, including code, are available in Appendix XX.

208 We then compared models as classifiers using their false positive and false
209 negative rates in three epidemiological scenarios. In applied settings, models
210 must often be evaluated on their performance as classifiers rather than just as
211 prediction engines (i.e. their ability to say a patient is COVID-19 positive or
212 negative, not simply the probability the patient might be COVID-19 positive or
213 negative). To generate a classification, a probability threshold must be chosen
214 over which patients are classified as COVID-19 positive.

215 Classifier performance was compared using ROC curves and error rates under
216 three epidemiological scenarios. ROC curves show the true and false positive
217 rates that each model can achieve. To extract the error rate under the epidemi-
218 ological scenarios (described below), we use the ROC calculations to identify
219 the probability threshold which most closely meets the scenario requirement
220 (see Table 1. Comparing specific scenarios allows classifier performance to be
221 demonstrated in relevant scenarios. Whether measuring classifier performance in




Figure 2: Schematic for rounds of model selection in the multivariate probit component of Model Classes 2 and 3. With 14 symptoms (only 5 shown here for demonstration purposes) and two covariates there are over 131000 possible model combinations. To make exploring these possible models computationally feasible and, to reduce the risk of overfitting, we carried out two rounds of model selection. First, the data are divided into temporal cross validation sets. The multivariate probit connects symptoms to the RT-PCR result through a correlation matrix. In the coarse model selection, the most complex feasible model (all symptoms and covariates) is fit to the training data. The estimated correlations between each symptom and the RT-PCR result are compared for each cross validation set. The symptoms that have non-zero correlations in a systematic direction (i.e. all positively or all negatively correlated with RT-PCR result) are retained. The process is then repeated on each retained set of symptoms until the four symptoms in each model class with the strongest correlation to RT-PCR result. We then conduct a more exhaustive fine model selection on all the possible permutations of the four symptoms and two covariates. In this round, each model is fit to training data and used to predict for the test set, and the quality of those predictions is measured using cross entropy scoring. The cross entropy score is then used to select the best predictive model for each level of model complexity. Only these final models are then used for classification. This reduces the set of models tested as classifiers from >131 000 to just four per model class.

Table 1: For each epidemiological scenario there is a requirement and a performance criterion. The requirement refers to a base level of performance the model must achieve; in general this will be a maximum acceptable error rate of some kind. The requirement determines a threshold for each model which most closely meets that requirement. The performance criterion is then used to determine which model performs the 'best' given that the requirement has been met.

Scenario Name	Requirement	Performance Criterion (Error)
1 Agnostic	Maximise correct classification rates	Sum of error rates
2 Rising Cases	Max. 20% false negative rate	False negative rate
3 Low-Level Cases	Max. 20% false positive rate	False positive rate

specific scenarios or more generally, decisions need to be made about the relative cost and acceptable levels of the two types of misclassification (false positives and negatives). We strongly emphasise that local context should be the guide in applying these methods.

In Scenario 1, we do not consider epidemiological context but simply weight false negative and false positive rates equally by aiming to maximise the overall correct classification rate. Scenario 2 corresponds to the current situation in Bangladesh at time of writing (July 2021), with COVID-19 cases beginning to rapidly increase again. Under these circumstances, false negatives are extremely costly relative to false positives due to the exponential growth of the disease. In Scenario 3, the pandemic is not declining but maintaining a steady rate of cases. In this situation, policy-makers may be keen to keep false positive diagnoses low to prevent lockdown fatigue and to keep the workforce active.

4. Results (~353 words)

A total of 1172 subjects had data available for the current analyses. The mean age of women participants (46.8430034% of the sample) was 37.13 (SD = 14.11), and for men (53% of the sample) was 35.94 (SD = 14.28). Participants were self-selecting and drawn from across Dhaka.

Model selection for Model Class 2 (syndromic data only) and 3 (syndromic and RAT data), each retained age as an explanatory variable and showed a marked decline in predictive power at more than 4 symptoms. The final four symptoms in order of importance (i.e. the most important symptom was retained in all of the final 4 models, the least important symptom was only retained in the 4 symptom model) were wet cough, runny nose, loss of smell and breathing problems for Model Class 2, and fever, wet cough, tiredness and diarrhoea for Model Class 3. For both Model Class 2 and Model Class 3 model selection retained age as a covariate but not gender.

In the comparison of model predictive performance, Model Class 1 (RAT only) performed worst with a cross entropy of 3.24 (cross entropy values further from

zero correspond to worse predictive performance). The median cross entropy values were between 2.52 and 2.59 for models in Class 2 (syndromic data only). Models in Class 3 (combined data model) performed best with cross entropy values between 1.44 and 1.45 (see Figure 3).

General model classification performance is shown by the full ROC curves for each model (Figure 4).

Scenario specific classification performance is shown in Figure 5. In Scenario 1 (“Agnostic,” see Table 1), the median error was 0.34 for models in Class 1 and Class 3 and between 0.98 and 1 for models in Class 2 (Figure 5). In Scenario 2 (“Rising Cases”), Model Class 1 was unable to meet the required false negative rate. The median errors were between 0.82 and 0.94 for models in Class 2, and 0.48 and 0.78 for models in Class 3 (Figure 5). In Scenario 3 (“Low-Level Cases”), the error in Class 1 was 0.02 and the median errors ranged from 0.14 to 0.19 for Class 2, and 0.08 to 0.19 for Class 3 (Figure 5).

5. Discussion (~1314 Words)

We have demonstrated that combining rapid antigen tests (RATs) with syndromic modelling yields better prediction of COVID-19 status and greater flexibility than each diagnostic individually. These improvements are non-trivial in real-world settings. In Bangladesh, there are currently 15 000 new cases being identified every day, using only the limited supply of RT-PCR, the pandemic growth is accelerating and every missed case has a compounding effect. Scenario 2 (“Rising Cases”) was developed with the need to keep false negative rates low and maps well onto the situation in Bangladesh (see Table 1). In this scenario, the combined data model (Model Class 3) false negative rate is 22 percentage points lower than that of the RAT only model (Model Class 1). Although the syndromic only model (Model Class 2) matches the combined models false negative rate, its false positive rate is 34 percentage points higher. These are large performance gains for any diagnostic but when deployed at the scale of Bangladesh and similar countries, these improvements represent catching tens of thousands of cases that would otherwise be missed. Furthermore, this boost is achieved with data that are already being collected in Bangladesh and other low- and middle- income countries. Outwith developing and rerunning the models presented in this paper, these improvements are essentially cost free and eminently scalable.

The pattern is similar in epidemiological Scenarios 1 (“Agnostic”) and 3 (“Low-Level Cases”), with the combined model class performing performing equally well or better than the other two classes (Figure 5). These three scenarios only offer snapshots of performance, however, and we strongly advocate defining model performance in terms of false negative and false positive rates with reference to local conditions. An indication of how these models will perform under any condition can be obtained by comparing the more generic model performance metrics for prediction and classification (Figures 3 and 4, respectively). These figures demonstrate both the added flexibility of the more complex model classes that allow them to be tailored to specific needs and the need to combine the high-quality but inflexible RAT results with the more




Figure 3: Predictive performance of candidate models. Interquartile ranges for the posterior cross entropy of the best candidate models at each level of model complexity tested under temporal cross-validation. Cross entropy is a measure of distance from the truth, so values closer to zero indicate better models. The intermediate complexity models perform best at prediction, although performance is similar across all the models within each model class (1: rapid antigen testing (RAT) only; 2: syndromic data only; and 3: combined RAT and syndromic data).




Figure 4: Receiver operating characteristics for rapid antigen testing (RAT) only approach (Model Class 1) and posterior mean (\pm posterior standard deviation) receiver operating characteristics for Class 2 (syndromic data only) and 3 (syndromic and RAT data) models. These curves demonstrate the performance of the model for any hypothetical scenario as defined by the axes (as opposed to Figure 5 which demonstrates model performance in specific epidemiological scenarios which are realisations of a single point in this space).




Figure 5: Performance of models under each scenario measured by errors defined in Table 2. Low errors correspond to better model performance. There is no error rate defined for the Model Class 1 (RAT only model) in Scenario 2 as the model failed to meet the requirement for that scenario (making the error functionally infinite).

flexible but lower quality syndromic data. Interestingly, the most of the Class 2 models performs approximately as well as chance except the simplest which performs worse than chance. A model that performs worse than random can still be useful if one takes the inverse decision. Even a flexible model which performs as well as random classification can be useful if those error rates reflect those needed in a given local situation. Fortunately, Model Class 3 is both flexible and performs better than random.

We have deliberately not emphasised the final symptoms chosen through model selection in this paper as we are focusing on prediction and classification for a unique sub-population: self-referring, symptomatic patients. We do, however, highlight that while fever and loss of smell were the two most important symptoms in the two classes of syndromic models, the other symptoms retained were different (with cough and wet cough retained in the combined syndromic and RAT model, Class 3, and loss of taste and vomiting in the syndromic only model, Class 2). Further research is needed to understand the mechanisms by which symptoms predict COVID-19 and by which RAT misses COVID-19. Of particular interest is whether individuals that are missed by RAT are less infectious, which could be explored by using Threshold Cycle (Ct) values from the RT-PCR to compare viral load with respect to prediction by the different methods [21]. We note also that, as expected, age was retained in model selection. We were, however, surprised that gender was removed during model selection. Gender is thought to play a major role in infection risk [23]. As we are looking to predict symptomatic

@Dirk - can you please clarify this or suggest reasons the model is performing so badly. The red line here is a univariate probit regression with one continuous covariate so I don't understand why it's performing so poorly unless the temporal cross validation sets are wildly different from each other?

317 COVID-19 in symptomatic individuals, generalised risk of infection is perhaps
318 less predictive than expected, potentially due to the balancing of risk and burden
319 [24].

320 Using a large sample collected under field-realistic conditions, we have rigor-
321 ously tested our approach. By taking a statistical modelling approach to case
322 identification, we are able to update our diagnostic process in real time, allowing
323 this method to readily adapt to new variants (or even new diseases) or new
324 priorities for resource allocation. The modelling frameworks we have used are
325 also sufficiently flexible to accommodate new data sources. Of particular interest
326 are extensions to include the “pandemic context” in the model using space-time
327 data. Furthermore, by using more sophisticated modelling structures that work
328 at the scale of probabilities, rather than binary tests, it is possible to tune error
329 rates to better reflect the local relative costs of false positives and false negatives.
330 Naturally, these strengths have complementary limitations. Our models require
331 updating in real-time and can only achieve good performance if the validation
332 data are of high quality. Similarly, targeting error rates is only sensible if those
333 rates properly reflect local conditions which is hard to do in practice. These
334 limitations should be seriously considered but the alternatives for imperfect
335 testing methods are diagnostics that cannot be tailored to local conditions at all
336 (and, as such may perform worse than a method which is sub-optimally tailored
337 to local conditions) or diagnostics which make these decisions implicitly and not
338 explicitly. We choose to make these decisions explicitly to allow them to be more
339 readily challenged, researched and improved upon. We also emphasise the need
340 for rigorous experimental design to ensure findings from the sample population
341 are applicable to the target population and the need for further research into
342 understanding error rate trade-offs in applied settings.

343 We believe that the combined syndromic and rapid antigen testing approach
344 represents the most promising approach to large-scale testing in low- and middle-
345 income countries for COVID-19 at present. By using the small amount of
346 RT-PCR testing possible and formally integrating multiple imperfect, non-gold-
347 standard methods, we can tune these diagnostics to our local conditions. We have
348 demonstrated that these improvements can be impressive in real-world scenarios,
349 and will have a large impact when scaled to the population sizes in low- and
350 middle-income countries. The methodology we have outlined here is applicable
351 to a wide range of diseases and settings across low- and middle-income countries.
352 One of the biggest challenges in diagnosing and tracking many diseases in
353 resource-limited settings is the low availability of access to gold-standard testing
354 (such as RT-PCR in the case of COVID-19) and high error rates of alternative
355 testing methods. In this paper, we have outlined the process for coupling a small
356 number of gold-standard tests with formal statistical integration of alternative
357 testing methods, to generate high quality diagnostic models. This process readily
358 maps onto many other case identification problems, including the diagnosis of
359 several neglected tropical diseases. For example, malaria (gold standard (GS) is
360 also RT-PCR, imperfect methods (IM) include antigen tests, syndromic diagnosis
361 and blood smears), schistosomiasis (GS: RT-PCR or autopsy; IM: Kato Katz
362 egg counts, antibody detection) and rabies (GS: fluorescent antibody test; IM:

light microscopy, differential diagnosis).

The management of global pandemics can only be done with global testing. While the quest to achieve this using only gold-standard diagnostic methods is laudable, it is also often impractical. Imperfect diagnostics are frequently imperfect in different ways, and these differences are ripe for statistical exploitation. What is more, these approaches are often more agile than gold-standard diagnostics in situations of flux, for example, in the early stages of new pandemics or disease strains, when fast responses are essential. By investing in understanding how to utilise the complementary strengths of imperfect testing and deploy the limited gold-standard testing available for validation, we can provide good quality testing at the scale needed to fight infectious diseases.

6. Funding (~26 words)

The Bill and Melinda Gates Foundation funded work by FAO (INV-022851), and University of Glasgow reports funding from Wellcome (207569/Z/17/Z). The authors declare no competing interests.

7. Acknowledgements (~67 words)

We would like to thank members of the community support teams in Bangladesh who have provided essential services throughout the pandemic. Earlier drafts of this manuscript benefited from the input of Daniel Haydon, Anne-Sophie Bonnet-Lebrun, Luca Nelli, Crinan Jarrett, Rita Claudia Cardoso Ribeiro, Halfan Ngowo, Heather McDevitt and Gina Bertolacci. The University of Glasgow COVID-19 in LMICs Group provided the environment in which to develop this work.

References (Max 30)

- [1] Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* 2020;25:2000045.
- [2] Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: Issues affecting the results. *Expert Review of Molecular Diagnostics* 2020;20:453–4.
- [3] Chowdhury R, Luhar S, Khan N, Choudhury SR, Matin I, Franco OH. Long-term strategies to control COVID-19 in low and middle-income countries: An options overview of community-based, non-pharmacological interventions. *European Journal of Epidemiology* 2020;35:743–8.
- [4] Vandenberg O, Martiny D, Rochas O, Belkum A van, Kozlakidis Z. Considerations for diagnostic COVID-19 tests. *Nature Reviews Microbiology* 2021;19:171–83.

- 396 [5] Cash R, Patel V. Has COVID-19 subverted global health? *The Lancet*
397 2020;395:1687–8.
- 398 [6] Olalekan A, Iwalokun B, Akinloye OM, Popoola O, Samuel TA, Akinloye
O. COVID-19 rapid diagnostic test could contain transmission in low-
and middle-income countries. *African Journal of Laboratory Medicine*
399 2020;9:1–8.
- 400 [7] Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F,
Gómez-Herruz P, et al. Panbio antigen rapid test is reliable to diagnose
SARS-CoV-2 infection in the first 7 days after the onset of symptoms.
401 *Journal of Clinical Virology* 2020;133:104659.
- 402 [8] Boum Y, Fai KN, Nikolay B, Mboringong AB, Bebell LM, Ndifon M,
et al. Performance and operational feasibility of antigen and antibody
rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic
patients in cameroon: A clinical, prospective, diagnostic accuracy study.
403 *The Lancet Infectious Diseases* 2021.
- 404 [9] Mak GC, Cheng PK, Lau SS, Wong KK, Lau C, Lam ET, et al. Evaluation
of rapid antigen test for detection of SARS-CoV-2 virus. *Journal of*
405 *Clinical Virology* 2020;129:104500.
- 406 [10] Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, Fan Y-P, et al. A rapid
advice guideline for the diagnosis and treatment of 2019 novel coronavirus
(2019-nCoV) infected pneumonia (standard version). *Military Medical*
407 *Research* 2020;7:1–23.
- 408 [11] Sim JXY, Conceicao EP, Wee LE, Aung MK, Seow SYW, Teo RCY, et
al. Utilizing the electronic health records to create a syndromic staff
surveillance system during the COVID-19 outbreak. *American Journal of*
409 *Infection Control* 2021;49:685–9.
- 410 [12] Undurraga EA, Chowell G, Mizumoto K. COVID-19 case fatality risk
by age and gender in a high testing setting in latin america: Chile,
411 march–august 2020. *Infectious Diseases of Poverty* 2021;10:1–1.
- 412 [13] Wenham C, Smith J, Morgan R. COVID-19: The gendered impacts of
the outbreak. *The Lancet* 2020;395:846–8.
- 413 [14] Mayorga L, Samartino CG, Flores G, Masuelli S, Sánchez MV, Mayorga
LS, et al. A modelling study highlights the power of detecting and
isolating asymptomatic or very mildly affected individuals for COVID-19
415 epidemic management. *BMC Public Health* 2020;20:1–1.
- 416 [15] Garry S, Abdelmagid N, Baxter L, Roberts N, Waroux O le P de, Ismail
S, et al. Considerations for planning COVID-19 treatment services in
humanitarian responses. *Conflict and Health* 2020;14:1–1.
- 417 [16] Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19
418 results: Hidden problems and costs. *The Lancet Respiratory Medicine*
2020;8:1167–8.
- 419

- 420 [17] West CP, Montori VM, Sampathkumar P. COVID-19 testing: The threat
of false-negative results. *Mayo clinic proceedings*, vol. 95, Elsevier; 2020,
421 p. 1127–9.
- 422 [18] Albert JH, Chib S. Bayesian analysis of binary and polychotomous re-
sponse data. *Journal of the American Statistical Association* 1993;88:669–
423 79.
- 424 [19] Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M,
et al. Stan: A probabilistic programming language. *Journal of Statistical*
425 *Software* 2017;76:1–32.
- 426 [20] Gneiting T, Raftery AE. Strictly proper scoring rules, prediction, and
estimation. *Journal of the American Statistical Association* 2007;102:359–
427 78.
- 428 [21] Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ,
et al. Field evaluation of a rapid antigen test (panbio™ COVID-19 ag
rapid test device) for COVID-19 diagnosis in primary healthcare centres.
429 *Clinical Microbiology and Infection* 2021;27:472–e7.
- 430 [22] Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA,
et al. Real-time tracking of self-reported symptoms to predict potential
431 COVID-19. *Nature Medicine* 2020;26:1037–40.
- 432 [23] Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for covid-19
severity and fatality: A structured literature review. *Infection* 2020:1–4.
433
- 434 [24] Joe W, Kumar A, Rajpal S, Mishra U, Subramanian S. Equal risk, unequal
burden? Gender differentials in COVID-19 mortality in india. *Journal of*
435 *Global Health Science* 2020;2.